Advanced search
Publication Cover
OncoTargets and Therapy Volume 11, 2018 - Issue
Submit an article Journal homepage
93
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients

Hong Jun Kim1 Division of Oncology and Hematology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Republic of Korea, [email protected]
,
Min Jee Jo2 Laboratory of Oncology, Graduate School of Medicine, Korea University, Seoul, Republic of Korea, [email protected]
,
Bo Ram Kim2 Laboratory of Oncology, Graduate School of Medicine, Korea University, Seoul, Republic of Korea, [email protected]
,
Jung Lim Kim2 Laboratory of Oncology, Graduate School of Medicine, Korea University, Seoul, Republic of Korea, [email protected]
,
Yoon A Jeong2 Laboratory of Oncology, Graduate School of Medicine, Korea University, Seoul, Republic of Korea, [email protected]
,
Yoo Jin Na2 Laboratory of Oncology, Graduate School of Medicine, Korea University, Seoul, Republic of Korea, [email protected]
,
Seong Hye Park2 Laboratory of Oncology, Graduate School of Medicine, Korea University, Seoul, Republic of Korea, [email protected]
,
Suk-young Lee1 Division of Oncology and Hematology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Republic of Korea, [email protected]
,
Dae-Hee Lee1 Division of Oncology and Hematology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Republic of Korea, [email protected];2 Laboratory of Oncology, Graduate School of Medicine, Korea University, Seoul, Republic of Korea, [email protected]
,
Baek-hui Kim3 Department of Pathology, College of Medicine, Korea University, Seoul, Republic of Korea
,
Young Do Yoo4 Laboratory of Molecular Cell Biology, Graduate School of Medicine, Korea University, Seoul, Republic of Korea
&
Sang Cheul Oh1 Division of Oncology and Hematology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, Republic of Korea, [email protected];2 Laboratory of Oncology, Graduate School of Medicine, Korea University, Seoul, Republic of Korea, [email protected]Correspondence[email protected]
 show all
Pages 4233-4246 | Published online: 23 Jul 2018

References

  • JemalACenterMMDeSantisCWardEMGlobal patterns of cancer incidence and mortality rates and trendsCancer Epidemiol Biomarkers Prev20101981893190720647400
  • JungKWWonYJKongHJCancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012Cancer Res Treat201547212714125761484
  • FauciASLongoDLKasperDLJamesonJLLoscalzoJHauserSLHarrison’s Principles of Internal Medicine17th edNew York; LondonMcGraw-Hill Medical2008
  • DeSantisCELinCCMariottoABCancer treatment and survivorship statistics, 2014CA Cancer J Clin201464425227124890451
  • ReckMRodríguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med2016201637518231833
  • BalkwillFCharlesKAMantovaniASmoldering and polarized inflammation in the initiation and promotion of malignant diseaseCancer Cell20057321121715766659
  • CoussensLMZitvogelLPaluckaAKNeutralizing tumor-promoting chronic inflammation: a magic bullet?Science2013339611728629123329041
  • NaARChungYMLeeSBParkSHLeeMSDo YooYA critical role for Romo1-derived ROS in cell proliferationBiochem Biophys Res Commun2008369267267818313394
  • WuWSThe signaling mechanism of ROS in tumor progressionCancer Metastasis Rev200625469570517160708
  • ChungYMKimJSYooYDA novel protein, Romo1, induces ROS production in the mitochondriaBiochem Biophys Res Commun2006347364965516842742
  • LeeSHChoiSILeeJSReactive oxygen species modulator 1 (Romo1) predicts poor outcomes in advanced non-small cell lung cancer patients treated with platinum-based chemotherapyCancer Res Treat201749114114927188201
  • LeeSHMinJWLeeJSReactive oxygen species modulator 1 (Romo1) overexpression is an independent predictor of poor survival in NSCLC patients who undergo surgical resectionLung Cancer2015871455225468147
  • ChungJSParkSParkSHOverexpression of Romo1 promotes production of reactive oxygen species and invasiveness of hepatic tumor cellsGastroenterology201214341084109422749933
  • KimHJJoMJKimBRReactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patientsPLoS One2017125e017683428472059
  • KimYWByzovaTVOxidative stress in angiogenesis and vascular diseaseBlood2014123562563124300855
  • LeeSParkYHChungJSYooYDRomo1 and the NF-κB pathway are involved in oxidative stress-induced tumor cell invasionInt J Oncol20154652021202825673177
  • DuaRGuiGIsackeCEndothelial adhesion molecules in breast cancer invasion into the vascular and lymphatic systemsEur J Surg Oncol200531882483216055299
  • StackerSAAchenMGJussilaLBaldwinMEAlitaloKLymphangiogenesis and cancer metastasisNat Rev Cancer20022857358312154350
  • FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
  • KaramanSDetmarMMechanisms of lymphatic metastasisJ Clin Invest2014124392292824590277
  • Ushio-FukaiMVEGF signaling through NADPH oxidase-derived ROSAntioxid Redox Signal20079673173917511588
  • TamWLWeinbergRAThe epigenetics of epithelial-mesenchymal plasticity in cancerNat Med201319111438144924202396
  • LadasEJJacobsonJSKennedyDDTeelKFleischauerAKellyKMAntioxidants and cancer therapy: a systematic reviewJ Clin Oncol200422351752814752075
  • DiemSSchmidSKrapfMNeutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumabLung Cancer201711117618128838390
  • BursteinHJKrilovLAragon-ChingJBClinical cancer advances 2017: annual report on progress against cancer from the American Society of Clinical OncologyJ Clin Oncol201735121341136728148207
  • Van CutsemECervantesAAdamRESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnn Oncol20162781386142227380959
  • HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
  • ElinavENowarskiRThaissCAHuBJinCFlavellRAInflammation-induced cancer: crosstalk between tumours, immune cells and microorganismsNat Rev Cancer2013131175924154716

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.